South America Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN, Antisense, and Other), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others)

South America Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN, Antisense, and Other), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations)

The genome editing market in South America is expected to grow from US$ 319.10 million in 2021 to US$ 1,003.03 million by 2028; it is estimated to grow at a CAGR of 17.8% from 2021 to 2028. According to the World Health Organization (WHO), cancer is the biggest cause of death in the region. Overall, the burden of cancer incidence and death is quickly increasing, reflecting both population aging and growth, as well as changes in the prevalence and distribution of the key cancer risk factors, many of which are related to socio-economic development. CANCER TODAY enabled a comprehensive assessment of the cancer burden. In 2020, based on the GLOBOCAN estimates of incidence, mortality, and prevalence for 2020 in 185 countries or territories for 36 cancer types by sex and age group. According to the recent estimates, the incidence of cancer has been increasing at an alarming rate, making hepatocellular carcinoma (HCC the fifth most common cancer in men and the seventh most common cancer in women. HCC is likely to contribute to ~5.6% of all human cancers, thereby increasing the burden in 2020. The HCC is known to be the second leading cause of cancer-related deaths worldwide. Almost 85% of HCCs occur in developing countries. Other types of liver cancers are cholangiocellular carcinoma (CCC), a malignant disease of the liver bile ducts, and hepatoblastoma. Hepatoblastoma is the most common malignant tumor of the liver in children. Thus, a rise in the prevalence of liver diseases, including chronic and acute diseases and microbial infections, increases the demand for liver models. A chromosomal abnormality can be detected in about one out of every 150 live births. Yet even this high incidence represents only a small fraction of chromosome mutations since the vast majority are lethal and result in prenatal death or stillbirth. Indeed, 50% of all first-trimester miscarriages and 20% of all second-trimester miscarriages are estimated to involve a chromosomally abnormal fetus. Although Down syndrome is the most well-known and well-recognized autosomal trisomies, it is only diagnosed in around one out of every 800 live births. Many cancer biology investigations are now using CRISPR as a standard approach. The CRISPR/Cas9 system has been shown to be effective in treating metastatic tumors, which is a big step toward discovering a cancer cure. The CRISPR-LNPs system contains a messenger RNA that encodes for the Cas9 CRISPR enzyme, which operates as molecular scissors to cut the DNA of cells. CRISPR-based studies have opened new doors to treating hereditary or developmental neurological disorders (HNDs) such as fragile X syndrome and Down syndrome. Thus, the increasing factors of genome editing are expected to boost the growth of the genome editing market during the forecast period.

The outbreak of COVID-19 pandemic stringently affected medical services in the South America region. Also, the South America region regions were profoundly affected due to the COVID-19 pandemic. For instance, countries such as Brazil, Argentina, Uruguay, Chile, Peru, Colombia have reported the highest number of positive cases and Brazil has registered the maximum number of deaths. The cell therapy instruments supply chain, which is already logistically complicated, has to face new challenges. The cell therapy instrument market has also witness some shortfall at the beginning of COVID 19 crisis owing to factors such as disruption in supply chain and demand due to lock down announced by majority of South America region countries

The South America genome editing market is segmented based on technology, application, and end user. Based on technology, the market is segmented into CRISPR, TALEN, antisense, and other. In 2021, CRISPR segment held the largest share in the market. The clustered regularly interspaced short palindromic repeats CRISPR are associated with the Cas genes that essential for adaptive immunity in selected bacteria and archaea. The CRISPR enables the organisms to respond the changes and elimination of invading genetic material. There are types of the CRISPR mechanisms have been adopted for genome-editing protocols. The first one is wild-type Cas9, second is mutated Cas9 and the third is nuclease-deficient Cas9. The CRISPR-Cas9 is faster, cheaper and more accurate than the other technologies of DNA editing and is used for the wide applications. It is considered to be the simplest, most versatile and precise method of genetic manipulation. The companies which offer CRISPR are Sangamo Therapeutics, Editas Medicine, Thermo Fisher Scientific, Horizon Discovery Groups among the others. Owing to the simple, fast and accurate property of the CRISPR the market for the segment is expected to grow at the fastest rate in the coming forecast years.

The overall South America genome editing market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining overview and forecast for the South America genome editing market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and to gain more analytical insights into the topic. The participants typically involved in this process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the South America genome editing market. THERMO FISHER SCIENTIFIC INC., MERCK KGaA, Lonza, Horizon Discovery Group plc., GenScript, New England Biolabs, Eurofins Scientific, and CRISPR Therapeutics are among the leading companies in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South America genome editing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South America genome editing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South America market trends and outlook coupled with the factors driving the genome editing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution